Trials / Completed
CompletedNCT00289562
Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia
A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients With B-Cell Acute Lymphoblastic Leukemia With an Option of Extended Use of Forodesine Hydrochloride
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (planned)
- Sponsor
- BioCryst Pharmaceuticals · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients with B-cell Acute Lymphoblastic Leukemia with an Option of Extended Use of Forodesine Hydrochloride
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | forodesine hydrochloride (BCX-1777) |
Timeline
- Start date
- 2004-09-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2006-02-10
- Last updated
- 2012-01-20
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00289562. Inclusion in this directory is not an endorsement.